Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist

@article{Ghin2014PharmacokineticIB,
  title={Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist},
  author={Martine G{\'e}hin and Patricia N. Sidharta and Carmela Gnerre and Alexander Treiber and Atef Halabi and Jasper Dingemanse},
  journal={European Journal of Clinical Pharmacology},
  year={2014},
  volume={71},
  pages={15-23}
}
PurposeSetipiprant, a selective oral CRTH2 antagonist, has been investigated for the treatment of allergic rhinitis and asthma. In vitro data showed that setipiprant has a weak induction potential on CYP3A4. An interaction at the hepatic level between setipiprant and CYP3A4 substrates was not expected even at the dosing regimen of 1,000 mg setipiprant b.i.d. due to the high plasma protein binding. However, at this dosing regimen, interactions at the gut level could not be excluded.MethodsIn… CONTINUE READING
BETA

Figures, Tables, and Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 38 REFERENCES

Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics.

  • Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • 2014
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…